Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ketamine plus talk therapy shows promise for stubborn depression

NCT ID NCT07706478

Recruiting now Disease control Sponsor: Senz Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial tests a treatment called ketamine-assisted psychotherapy (KAP) for people with treatment-resistant depression. Participants receive intravenous ketamine along with psychological support and integration sessions. The goal is to see if this combination helps improve emotional processing and leads to lasting relief from depression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ketamine combined with psychotherapy
What this could lead to
If successful, this could offer a new treatment option for people with depression that hasn't responded to standard therapies.
What could go wrong
This is an early-stage, open-label trial with no placebo group, so results may be influenced by expectation. Ketamine can cause side effects like dissociation and blood pressure changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT RESISTANT DEPRESSION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • SENZ

    RECRUITING

    Doorn, Utrecht, 3941ZS, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.